Candidiasis, a fungal infection caused by the overgrowth of Candida species, commonly affects areas such as the mouth, throat, gut, and genital regions. The primary methods of treating candidiasis involve antifungal medications, which can be either topical (applied to the affected area) or oral (ingested), depending on the severity and location of the infection.
Candidiasis therapeutics encompass various treatment approaches, including medication, surgery, and other interventions. Medication involves the use of pharmaceutical drugs to manage or alleviate the condition. The treatments target specific anatomical sites such as oral candidiasis, vulvovaginal candidiasis, cutaneous candidiasis, invasive candidiasis, and systemic candidiasis. These medications can be administered through various routes, including injectable, oral, and others, catering to both adult and pediatric patients. The end-users for these treatments include hospitals, homecare settings, specialty clinics, and other healthcare facilities.
Note that the outlook for this market is being affected by rapid changes in trade relations and tariffs globally. The report will be updated prior to delivery to reflect the latest status, including revised forecasts and quantified impact analysis. The report's Recommendations and Conclusions sections will be updated to give strategies for entities dealing with the fast-moving international environment.
The sharp rise in U.S. tariffs and the resulting trade tensions in spring 2025 are having a significant impact on the healthcare sector, especially in the supply of essential medical devices, diagnostic equipment, and pharmaceuticals. Hospitals and healthcare providers are grappling with higher costs for imported surgical tools, imaging systems, and consumables like syringes and catheters, many of which have limited domestic substitutes. These escalating expenses are putting pressure on healthcare budgets, prompting some providers to delay equipment upgrades or pass increased costs on to patients. Furthermore, tariffs on raw materials and components are disrupting the manufacturing of vital drugs and devices, leading to supply chain delays. In response, the industry is adopting diversified sourcing strategies, expanding local production where feasible, and pushing for tariff exemptions on critical medical products.
The candidiasis therapeutics market research report is one of a series of new reports from The Business Research Company that provides candidiasis therapeutics market statistics, including candidiasis therapeutics industry global market size, regional shares, competitors with a candidiasis therapeutics market share, detailed candidiasis therapeutics market segments, market trends and opportunities, and any further data you may need to thrive in the candidiasis therapeutics industry. This candidiasis therapeutics market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The candidiasis therapeutics market size has grown steadily in recent years. It will grow from $3.19 billion in 2024 to $3.29 billion in 2025 at a compound annual growth rate (CAGR) of 3.0%. The growth in the historic period can be attributed to increased incidence of candidiasis, antibiotic use and resistance, hospital-acquired infections, shift in fungal resistance patterns, awareness and education programs.
The candidiasis therapeutics market size is expected to see steady growth in the next few years. It will grow to $3.83 billion in 2029 at a compound annual growth rate (CAGR) of 3.9%. The growth in the forecast period can be attributed to precision medicine approaches, global antifungal stewardship programs, increasing prevalence of candida auris, global efforts against antifungal resistance. Major trends in the forecast period include advancements in drug delivery technologies, telemedicine and remote patient monitoring, patient-centric care, combination therapies, collaborative research initiatives.
The forecast of 3.9% growth over the next five years reflects a slight reduction of 0.1% from the previous projection. This reduction is primarily due to the impact of tariffs between the US and other countries. Trade tensions could hinder U.S. infectious disease management by inflating prices of echinocandins and antifungal IV formulations developed in Spain and India, resulting in delayed treatment initiation and higher hospital pharmacy costs. The effect will also be felt more widely due to reciprocal tariffs and the negative effect on the global economy and trade due to increased trade tensions and restrictions.
The increasing prevalence of fungal infections is expected to drive the growth of the candidiasis therapeutics market. Fungal infections, which affect the skin, mucous membranes, and internal organs, are more common in individuals with weakened immune systems. This growing incidence of infections, particularly candidiasis, creates opportunities for manufacturers to develop and provide specialized, effective antifungal drugs that target the underlying pathogens. These drugs aim to alleviate symptoms, prevent complications, promote recovery, reduce the spread of Candida infections in healthcare settings, and improve patient outcomes. For instance, in January 2024, the University of Minnesota, a U.S.-based research institution, reported that fungal infections cause more than 3.75 million deaths annually, with about 2.55 million deaths directly linked to fungal diseases. As a result, the rising number of fungal infections is expected to propel the candidiasis therapeutics market.
The increasing number of clinical trials is expected to further fuel the growth trajectory of the candidiasis therapeutics market. Clinical trials serve as pivotal research studies aimed at assessing the safety and efficacy of novel medical treatments, interventions, drugs, or devices in human subjects. Within the domain of candidiasis therapeutics, these trials play a crucial role by offering a systematic and stringent evaluation platform for testing the safety and effectiveness of potential treatments. As reported by ClinicalTrials.gov in May 2023, the number of registered clinical trials surged to around 437,533 in 2023, compared to 399,499 registered studies in 2022 across all 50 states of the United States and spanning 221 countries. This increase underscores the rising momentum and significance of clinical trials in shaping the landscape of candidiasis therapeutics. Consequently, the burgeoning number of clinical trials emerges as a key factor driving the growth of the candidiasis therapeutics market.
Leading companies operating within the candidiasis therapeutics market are dedicatedly engaged in developing innovative drugs, such as BREXAFEMME (ibrexafungerp tablets), aimed at mitigating the occurrence of recurrent vulvovaginal candidiasis (RVVC) in adult women. BREXAFEMME (ibrexafungerp tablets) constitutes an oral, non-azole medication designed for the treatment of vulvovaginal candidiasis (VVC) and reducing the incidence of recurrent vulvovaginal candidiasis (RVVC), commonly known as chronic yeast infections. For instance, in December 2022, Scynexis Inc., a prominent US-based pharmaceutical company, secured approval from the US Food and Drug Administration (FDA) for BREXAFEMME (ibrexafungerp tablets). The medication targets Candida albicans, the fungus responsible for VVC, by obstructing its growth. Notably, BREXAFEMME is deemed a safe and effective treatment option for vulvovaginal candidiasis (VVC), available solely through prescription, with a recommended dosage of one 150-mg capsule taken orally once daily for a single day. This innovative drug stands as a promising advancement in addressing candidiasis, offering a viable treatment solution while navigating potential concerns related to adverse drug effects.
In May 2023, GSK plc, a prominent UK-based pharmaceutical company, finalized the acquisition of Licensing rights for ibrexafungerp from Scynexism Inc. in a transaction amounting to $90 million. This strategic acquisition grants GSK exclusive rights to further the development and commercialization of ibrexafungerp drugs, a groundbreaking antifungal medication designed for the treatment of vulvovaginal candidiasis (VVC). The acquisition is aimed at expediting the advancement and market availability of ibrexafungerp. Scynexism Inc., a notable US-based pharmaceutical company specializing in therapeutic solutions for fungal diseases, including candidiasis, initially developed this innovative medication.
Major companies operating in the candidiasis therapeutics market report are Pfizer Inc., Biocon Limited, Torrent Pharmaceuticals Ltd., F. Hoffmann-La Roche Ltd., Merck & Co. Inc., AbbVie Inc., Bayer AG, Novartis AG, Sanofi S.A., AstraZeneca plc., GSK plc., Amgen Inc., Teva Pharmaceutical Industries Ltd., Astellas Pharma Inc., Cipla Inc., Bruker Corporation, Lupin Limited, Galapagos NV, Basilea Pharmaceutica Ltd., WOCKHARDT Limited, Pacgen Life Science Corporation, Cidara Therapeutics Inc., Ablynx NV, Amplyx Pharmaceuticals Inc., NovaDigm Therapeutics Inc., SCYNEXIS Inc., Medivir AB, Mycovia Pharmaceuticals Inc., NovaBiotics Inc., Matinas BioPharma Holdings Inc.
North America was the largest region in the candidiasis therapeutics market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the candidiasis therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa
The countries covered in the candidiasis therapeutics market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain
The candidiasis therapeutics market consists of revenues earned by entities by providing services such as medication services, diagnostic tests, consultation services, and medical monitoring services. The market value includes the value of related goods sold by the service provider or included within the service offering. The candidiasis therapeutics market also includes sales of topical creams and ointments, oral medications, medical devices, probiotics, nutritional supplements and antifungal medications that are used in providing these services. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Candidiasis Therapeutics Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses on candidiasis therapeutics market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, post-pandemic supply chain realignment, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
- Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for candidiasis therapeutics ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The candidiasis therapeutics market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include:
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.
Scope
- Markets Covered:1) By Treatment Type: Medication; Surgery; Other Treatments
- 2) By Anatomy Type: Oral Candidiasis; Vulvovaginal Candidiasis; Cutaneous Candidiasis; Invasive Candidiasis; Systemic Candidiasis
- 3) By Mode Of Administration: Injectable; Oral; Other Mode Of Administrations
- 4) By Patient Population: Adults; Pediatrics
- 5) By End User: Hospitals; Homecare; Specialty Clinics; Other End Users
- Subsegments:
- 1) By Medication: Antifungal Drugs; Topical Treatments; Systemic Treatments
- 2) By Surgery: Surgical Debridement; Organ Removal
- 3) By Other Treatments: Probiotics; Home Remedies; Lifestyle Modifications
- Companies Mentioned: Pfizer Inc.; Biocon Limited; Torrent Pharmaceuticals Ltd.; F. Hoffmann-La Roche Ltd.; Merck & Co. Inc.; AbbVie Inc.; Bayer AG; Novartis AG; Sanofi S.A.; AstraZeneca plc.; GSK plc.; Amgen Inc.; Teva Pharmaceutical Industries Ltd.; Astellas Pharma Inc.; Cipla Inc.; Bruker Corporation; Lupin Limited; Galapagos NV; Basilea Pharmaceutica Ltd.; WOCKHARDT Limited; Pacgen Life Science Corporation; Cidara Therapeutics Inc.; Ablynx NV; Amplyx Pharmaceuticals Inc.; NovaDigm Therapeutics Inc.; SCYNEXIS Inc.; Medivir AB; Mycovia Pharmaceuticals Inc.; NovaBiotics Inc.; Matinas BioPharma Holdings Inc.
- Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
- Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
- Time Series: Five years historic and ten years forecast.
- Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
- Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
- Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
- Delivery Format: PDF, Word and Excel Data Dashboard.
Table of Contents
1. Executive Summary
2. Candidiasis Therapeutics Market Characteristics
3. Candidiasis Therapeutics Market Trends And Strategies
4. Candidiasis Therapeutics Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market
- 4.1. Supply Chain Impact from Tariff War & Trade Protectionism
5. Global Candidiasis Therapeutics Growth Analysis And Strategic Analysis Framework
- 5.1. Global Candidiasis Therapeutics PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
- 5.2. Analysis Of End Use Industries
- 5.3. Global Candidiasis Therapeutics Market Growth Rate Analysis
- 5.4. Global Candidiasis Therapeutics Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
- 5.5. Global Candidiasis Therapeutics Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
- 5.6. Global Candidiasis Therapeutics Total Addressable Market (TAM)
6. Candidiasis Therapeutics Market Segmentation
- 6.1. Global Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Medication
- Surgery
- Other Treatments
- 6.2. Global Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Oral Candidiasis
- Vulvovaginal Candidiasis
- Cutaneous Candidiasis
- Invasive Candidiasis
- Systemic Candidiasis
- 6.3. Global Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Injectable
- Oral
- Other Mode Of Administrations
- 6.4. Global Candidiasis Therapeutics Market, Segmentation By Patient Population, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Adults
- Pediatrics
- 6.5. Global Candidiasis Therapeutics Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Hospitals
- Homecare
- Specialty Clinics
- Other End Users
- 6.6. Global Candidiasis Therapeutics Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Antifungal Drugs
- Topical Treatments
- Systemic Treatments
- 6.7. Global Candidiasis Therapeutics Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Surgical Debridement
- Organ Removal
- 6.8. Global Candidiasis Therapeutics Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- Probiotics
- Home Remedies
- Lifestyle Modifications
7. Candidiasis Therapeutics Market Regional And Country Analysis
- 7.1. Global Candidiasis Therapeutics Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 7.2. Global Candidiasis Therapeutics Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
8. Asia-Pacific Candidiasis Therapeutics Market
- 8.1. Asia-Pacific Candidiasis Therapeutics Market Overview
- Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
- 8.2. Asia-Pacific Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.3. Asia-Pacific Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 8.4. Asia-Pacific Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
9. China Candidiasis Therapeutics Market
- 9.1. China Candidiasis Therapeutics Market Overview
- 9.2. China Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.3. China Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
- 9.4. China Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
10. India Candidiasis Therapeutics Market
- 10.1. India Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.2. India Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 10.3. India Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
11. Japan Candidiasis Therapeutics Market
- 11.1. Japan Candidiasis Therapeutics Market Overview
- 11.2. Japan Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.3. Japan Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 11.4. Japan Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
12. Australia Candidiasis Therapeutics Market
- 12.1. Australia Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.2. Australia Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 12.3. Australia Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
13. Indonesia Candidiasis Therapeutics Market
- 13.1. Indonesia Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.2. Indonesia Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 13.3. Indonesia Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
14. South Korea Candidiasis Therapeutics Market
- 14.1. South Korea Candidiasis Therapeutics Market Overview
- 14.2. South Korea Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.3. South Korea Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 14.4. South Korea Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
15. Western Europe Candidiasis Therapeutics Market
- 15.1. Western Europe Candidiasis Therapeutics Market Overview
- 15.2. Western Europe Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.3. Western Europe Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 15.4. Western Europe Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
16. UK Candidiasis Therapeutics Market
- 16.1. UK Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.2. UK Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 16.3. UK Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
17. Germany Candidiasis Therapeutics Market
- 17.1. Germany Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.2. Germany Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 17.3. Germany Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
18. France Candidiasis Therapeutics Market
- 18.1. France Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.2. France Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 18.3. France Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
19. Italy Candidiasis Therapeutics Market
- 19.1. Italy Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.2. Italy Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 19.3. Italy Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
20. Spain Candidiasis Therapeutics Market
- 20.1. Spain Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.2. Spain Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 20.3. Spain Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
21. Eastern Europe Candidiasis Therapeutics Market
- 21.1. Eastern Europe Candidiasis Therapeutics Market Overview
- 21.2. Eastern Europe Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.3. Eastern Europe Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 21.4. Eastern Europe Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
22. Russia Candidiasis Therapeutics Market
- 22.1. Russia Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.2. Russia Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 22.3. Russia Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
23. North America Candidiasis Therapeutics Market
- 23.1. North America Candidiasis Therapeutics Market Overview
- 23.2. North America Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.3. North America Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 23.4. North America Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
24. USA Candidiasis Therapeutics Market
- 24.1. USA Candidiasis Therapeutics Market Overview
- 24.2. USA Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.3. USA Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 24.4. USA Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
25. Canada Candidiasis Therapeutics Market
- 25.1. Canada Candidiasis Therapeutics Market Overview
- 25.2. Canada Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.3. Canada Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 25.4. Canada Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
26. South America Candidiasis Therapeutics Market
- 26.1. South America Candidiasis Therapeutics Market Overview
- 26.2. South America Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.3. South America Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 26.4. South America Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
27. Brazil Candidiasis Therapeutics Market
- 27.1. Brazil Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.2. Brazil Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 27.3. Brazil Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
28. Middle East Candidiasis Therapeutics Market
- 28.1. Middle East Candidiasis Therapeutics Market Overview
- 28.2. Middle East Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.3. Middle East Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 28.4. Middle East Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
29. Africa Candidiasis Therapeutics Market
- 29.1. Africa Candidiasis Therapeutics Market Overview
- 29.2. Africa Candidiasis Therapeutics Market, Segmentation By Treatment Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.3. Africa Candidiasis Therapeutics Market, Segmentation By Anatomy Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
- 29.4. Africa Candidiasis Therapeutics Market, Segmentation By Mode Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
30. Candidiasis Therapeutics Market Competitive Landscape And Company Profiles
- 30.1. Candidiasis Therapeutics Market Competitive Landscape
- 30.2. Candidiasis Therapeutics Market Company Profiles
- 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.2. Biocon Limited Overview, Products and Services, Strategy and Financial Analysis
- 30.2.3. Torrent Pharmaceuticals Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.4. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
- 30.2.5. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
31. Candidiasis Therapeutics Market Other Major And Innovative Companies
- 31.1. AbbVie Inc.
- 31.2. Bayer AG
- 31.3. Novartis AG
- 31.4. Sanofi S.A.
- 31.5. AstraZeneca plc.
- 31.6. GSK plc.
- 31.7. Amgen Inc.
- 31.8. Teva Pharmaceutical Industries Ltd.
- 31.9. Astellas Pharma Inc.
- 31.10. Cipla Inc.
- 31.11. Bruker Corporation
- 31.12. Lupin Limited
- 31.13. Galapagos NV
- 31.14. Basilea Pharmaceutica Ltd.
- 31.15. WOCKHARDT Limited
32. Global Candidiasis Therapeutics Market Competitive Benchmarking And Dashboard
33. Key Mergers And Acquisitions In The Candidiasis Therapeutics Market
34. Recent Developments In The Candidiasis Therapeutics Market
35. Candidiasis Therapeutics Market High Potential Countries, Segments and Strategies
- 35.1 Candidiasis Therapeutics Market In 2029 - Countries Offering Most New Opportunities
- 35.2 Candidiasis Therapeutics Market In 2029 - Segments Offering Most New Opportunities
- 35.3 Candidiasis Therapeutics Market In 2029 - Growth Strategies
- 35.3.1 Market Trend Based Strategies
- 35.3.2 Competitor Strategies
36. Appendix
- 36.1. Abbreviations
- 36.2. Currencies
- 36.3. Historic And Forecast Inflation Rates
- 36.4. Research Inquiries
- 36.5. The Business Research Company
- 36.6. Copyright And Disclaimer
